Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbetocin Nasal Spray for Hyperphagia in Prader-Willi Syndrome
2023-506200-24-00Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- May 2024
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Carbetocin Nasal Spray with Placebo (2 arms). Primary endpoint: Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score - change from Baseline at Week 12. Started May 2024; status: completed.
02
Drugs
carbetocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2023-506200-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506200-24-00.